Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Autolus Therapeutics (AUTL) over the last 4 years, with Sep 2025 value amounting to $35.5 million.

  • Autolus Therapeutics' Cash from Investing Activities rose 470.71% to $35.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$311.7 million, marking a year-over-year decrease of 1930.18%. This contributed to the annual value of -$394.6 million for FY2024, which is 3491.41% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Cash from Investing Activities of $35.5 million as of Q3 2025, which was down 62.94% from $95.9 million recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Cash from Investing Activities high stood at $95.9 million for Q2 2025, and its period low was -$383.6 million during Q4 2024.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$3.6 million (2023), whereas its average is -$36.7 million.
  • The largest annual percentage gain for Autolus Therapeutics' Cash from Investing Activities in the last 5 years was 11,504.88% (2025), contrasted with its biggest fall of 11,072.05% (2025).
  • Quarterly analysis of 5 years shows Autolus Therapeutics' Cash from Investing Activities stood at -$1.6 million in 2021, then soared by 70.57% to -$2.6 million in 2022, then plummeted by 66.25% to -$4.4 million in 2023, then skyrocketed by 80.84% to -$383.6 million in 2024, then surged by 470.71% to $35.5 million in 2025.
  • Its Cash from Investing Activities stands at $35.5 million for Q3 2025, versus $95.9 million for Q2 2025 and -$59.5 million for Q1 2025.